Hillman Cancer Center

The UPMC Hillman Cancer Center (Hillman), previously known as the University of Pittsburgh Cancer Institute (UPCI), is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center located in the Shadyside neighborhood of Pittsburgh, Pennsylvania.

It is the only NCI-designated cancer center in Western Pennsylvania, and comprises of collaborative academic and research efforts between the University of Pittsburgh, the University of Pittsburgh Medical Center (UPMC), and Carnegie Mellon University. Hillman provides clinical cancer care to around 74,000 patients, who are treated at its facilities both at the Hillman Cancer Center location and at UPMC-affiliated sites across several states and countries.

Founded in 1984, Hillman achieved NCI-designation in 1990 and has received nearly $200 million in funding from the National Cancer Institute. It focuses on four key research areas of molecular and medical oncology, including cancer development and progression, identification of new biomarkers, development of novel therapeutics, and cancer prevention measures.

In 2017, Robert L. Ferris was appointed as the director of the UPCI and UPMC Cancer Centers, and in 2020, Hillman received a five-year renewal as a comprehensive cancer center from the NCI and was awarded a $30 million grant. It also offers education, training programs and fellowships, in conjunction with related schools within the University of Pittsburgh, and recently completed a three-year expansion project in June 2021.